Stricter rules are in store for CDx stakeholders in the EU but it’s not all bad news.
Sylvie Le Glédic, Sabah Malek
2013 – SCRIP Regulatory Affairs
Download the full publication now
Fill in the form to download the content
PublicationIVD
The Proposed EU IVD Regulation and its Impact on Companion Diagnostic Development
All our resources
More resources
webinar
EMA
How to master both Marketing Authorization and Joint Clinical Assessment successfully?
The European Union is transforming its health technology assessment process with the introduction of the Joint Clinical Assessment (JCA) under…
blog
FDA
Accelerating Innovation: FDA Expedited Programs 101
In the fast-paced world of biotech innovation, time is of the essence. For European biotech ventures eyeing entry into the…
blog
FDA
Achieve Success for Your First US Product Application – Pathway to IND
Embarking on the journey to expand into the United States market is a pivotal moment for any European biotech company.…
blog
Microbiome
A deep dive into the regulatory framework for Phage Medicinal Products
Phages, also known as Bacteriophages, are viruses that infect specific bacteria and provoke their death via lytic activity. They are…
